Paper Details

  1. Home
  2. Paper Details

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Author: BaldiniLuca, BenevoloGiulia, BoccadoroMario, BringhenSara, CalleaVincenzo, CavalliMaide, CicconeGiovannino, FalconeAntonietta Pia, GottardiDaniela, GrassoMariella, GuglielmelliTommasina, LaroccaAlessandra, LeonardiGiovanna, MontefuscoVittorio, MorabitoFortunato, MustoPellegrino, NozzoliChiara, OffidaniMassimo, PalumboAntonio, PatriarcaFrancesca, PetrucciMaria Teresa, RiaRoberto, RizzoManuela, RossiDavide

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase III study examined the efficacy of the four-drug combination of bortezomib-melphalan-prednisone-thalidomide (VMPT) followed by maintenance with bortezomib-thalidomide (VMPT-VT) compared with VMP treatment alone in untreated multiple myeloma patients.
Paper Details　
Original Abstract of the Article :
The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma. This phase III study examined the efficacy of the four-drug combination of bortezomib-melphalan-prednisone-thalidomide (VMPT) followed by maintenance with bortezomib-thalidomide (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2010.29.8216

データ提供：米国国立医学図書館（NLM）

A New Standard of Care for Multiple Myeloma: VMPT Followed by VT

Multiple myeloma, a type of blood cancer, presents a significant challenge for patients and clinicians. This study examines the efficacy of a new four-drug combination, bortezomib-melphalan-prednisone-thalidomide (VMPT), followed by maintenance with bortezomib-thalidomide (VT), compared to the standard three-drug combination, bortezomib-melphalan-prednisone (VMP), in patients with newly diagnosed multiple myeloma who are not eligible for stem-cell transplantation.

VMPT Followed by VT: A Potential Improvement in Multiple Myeloma Treatment

The study found that VMPT followed by VT demonstrated promising results, potentially offering advantages over VMP alone. This combination may lead to improved response rates, longer progression-free survival, and potentially longer overall survival. While these findings are encouraging, further research is needed to confirm these benefits and to establish the optimal duration of treatment for each approach.

A Step Forward in the Fight Against Multiple Myeloma

This study offers a glimpse into the future of multiple myeloma treatment. The findings suggest that VMPT followed by VT may be a valuable addition to the arsenal of therapies available for patients with this type of cancer. This research underscores the importance of ongoing research and innovation in developing more effective treatments to improve the lives of individuals battling this challenging disease. Just as a camel navigates a desert landscape with determination, researchers are committed to finding new solutions to combat the complexities of cancer.

Dr.Camel's Conclusion

This study highlights the potential benefits of using VMPT followed by VT as a new standard of care for multiple myeloma patients ineligible for stem-cell transplantation. The findings suggest that this combination may lead to improved response rates and potentially longer survival. Further research is needed to confirm these benefits and to establish optimal treatment durations for each approach.

Date :
  1. Date Completed 2011-01-03
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

20940200

DOI: Digital Object Identifier

10.1200/JCO.2010.29.8216

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.